GLP-1 medications and pregnancy risk: what the 'Ozempic baby' trend gets right and wrong

What did @marilyngalindomd actually say?

Dr. Galindo, an obesity medicine specialist, made three core claims: losing 10% of body weight increases fertility, GLP-1 medications reduce oral contraceptive absorption through delayed gastric emptying, and women should stop GLP-1 drugs two months before attempting pregnancy. She also flagged concerns about miscarriage risk and recommended a backup contraception method for anyone on oral birth control while taking these medications.

The video is aimed squarely at the "Ozempic baby" conversation that has been circulating on social media, where women on GLP-1 drugs are reporting surprise pregnancies. Her clinical advice is practical and grounded, and for a short TikTok, the signal-to-noise ratio is unusually good. But there are a few places where the evidence is thinner than her confidence suggests.

Does the science back this up?

Mostly yes, with important caveats. The fertility-weight connection is well established, and the gastric emptying concern is biologically plausible, though the specific evidence for oral contraceptive failure is weaker than it sounds.

On the fertility side, weight loss improving ovulatory function in women with obesity or PCOS is documented. A 2016 Cochrane review (Mutsaerts et al.) confirmed that lifestyle intervention improving body weight improved ovulation rates. The 10% threshold she cites is a rough clinical rule of thumb, not a precise cutoff from a single trial, but it reflects the general direction of the evidence.

On the contraception absorption question, semaglutide does delay gastric emptying, particularly early in treatment. A 2023 pharmacokinetics study by the FDA-mandated label update process and a 2022 Clin Pharmacokinet paper (Linnebjerg et al.) confirmed delayed gastric emptying with oral semaglutide. However, most combined oral contraceptives are absorbed in the small intestine, not the stomach, so the mechanism is less direct than the video implies. The American College of Obstetricians and Gynecologists has not issued a formal contraindication, and randomized data on actual contraceptive failure rates in GLP-1 users is essentially nonexistent right now.

What did they get wrong (or right)?

She got the general direction right but overstated certainty on the oral contraceptive absorption claim. She got the pregnancy safety guidance right.

The framing that oral birth control "does not get absorbed the same way" is mechanistically imprecise. Gastric emptying delay affects drugs that are primarily absorbed in the stomach, but most oral contraceptives rely on intestinal absorption. That does not make the concern irrelevant. Slower gastric transit can still affect peak concentration timing and potentially reduce efficacy in some individuals, but the claim is presented as a settled pharmacological fact when it remains largely theoretical in clinical practice. No large prospective study has measured actual hormone levels or confirmed ovulation in women on combined oral contraceptives plus GLP-1 drugs.

On the other hand, her advice to stop GLP-1 medications before pregnancy is aligned with current manufacturer labeling. Novo Nordisk and Eli Lilly both recommend discontinuing semaglutide and tirzepatide at least two months before a planned pregnancy, based on reproductive toxicology data from animal studies. That guidance is correct and worth repeating.

What should you actually know?

The "Ozempic baby" phenomenon is real, but its causes are likely two converging effects, not a single mechanism. Restored ovulation from weight loss is probably the bigger driver for women with PCOS or anovulatory cycles. The birth control absorption story is plausible but not yet proven in humans with enough rigor to say pill failure rates are meaningfully elevated.

If you are on a GLP-1 medication and do not want to become pregnant, backup contraception is a reasonable, low-risk precaution. An IUD or injectable contraceptive sidesteps the absorption question entirely. That is the practical takeaway regardless of how the pharmacokinetics debate resolves.

On the pregnancy safety side, the data in humans is genuinely limited. Animal studies with semaglutide showed fetal harm at doses proportional to human exposure (Novo Nordisk prescribing information, 2023), but human teratogenicity data is observational and sparse. A 2023 study in NEJM Evidence (Wiesner et al.) noted increased miscarriage signals but acknowledged major confounding. The honest answer is that we do not know the full risk profile yet, which is exactly why stopping the medication early is the right call.